Abstract: An abnormality diagnosis device of an in-cylinder pressure sensor is provided. The device carries out a performance determination in which a performance quality of the sensor is determined based on an electric signal inputted from the sensor. The device carries out a first determination in which the performance determination is performed at a given timing, a performance recovery in which a given deposit removal control is executed in which a deposit accumulating inside the combustion chamber is removed when the performance quality of the in-cylinder pressure sensor is determined to fall below a given reference value, and a second determination in which the performance determination is carried out again after the performance recovery. In the second determination, the in-cylinder pressure sensor is diagnosed as abnormal when the performance quality of the sensor is determined to fall below the given reference value.

Abstract: A failure diagnosis device for an in-cylinder pressure sensor is provided, which includes an in-cylinder pressure sensor, and an engine controller comprised of circuitry configured to execute a diagnosis module into which a signal of the sensor is inputted, to diagnose a failure of the sensor based on the signal. The diagnosis module includes a reading module configured to read the signal of the sensor within a specific crank angle range, a reference phase determining module configured to determine a reference phase that is a phase of a pressure change accompanying a volume change of the combustion chamber, and a failure determining module configured to determine that the sensor has failed, when the failure determining module determines a phase of the read signal of the sensor is delayed by an amount exceeding a predefined threshold from the determined reference phase.

Abstract: A failure diagnosis system for an in-cylinder pressure sensor is provided, which includes an in-cylinder pressure sensor, a fuel injection valve, an engine controller including an engine control module and a diagnosis module. The engine control module controls the fuel injection valve to stop the supply of fuel to the engine, when a fuel cut condition is satisfied while the automobile travels. The diagnosis module includes a limiting module configured to limit an execution of the failure diagnosis of the in-cylinder pressure sensor until the diagnosis module determines that a given period has lapsed after the stop of fuel supply to the engine. The diagnosis module reads a signal of the in-cylinder pressure sensor when the given period has lapsed after the stop of the fuel supply to the engine, and diagnoses the failure of the in-cylinder pressure sensor based on the read signal of the in-cylinder pressure sensor.

Abstract: A failure diagnosis device for an in-cylinder pressure sensor includes an in-cylinder pressure sensor, and a controller comprised of circuitry configured to execute a diagnosis module into which a signal of the in-cylinder pressure sensor is inputted and configured to diagnose a failure of the sensor based on the signal. The diagnosis module includes a reading module configured to read the signals of the in-cylinder pressure sensor at a first timing that is a timing retarded by a specific crank angle from a compression top dead center, and at a second timing that is a timing advanced by the specific crank angle from the compression top dead center, and a failure determining module configured to determine that the in-cylinder pressure sensor has failed when the failure determining module determines that a difference between signal values at the first timing and at the second timing exceeds a predefined threshold.

Abstract: An abnormality diagnosis device of an in-cylinder pressure sensor is provided. The device carries out a performance determination in which a performance quality of the sensor is determined based on an electric signal inputted from the sensor. The device carries out a first determination in which the performance determination is performed at a given timing, a performance recovery in which a given deposit removal control is executed in which a deposit accumulating inside the combustion chamber is removed when the performance quality of the in-cylinder pressure sensor is determined to fall below a given reference value, and a second determination in which the performance determination is carried out again after the performance recovery. In the second determination, the in-cylinder pressure sensor is diagnosed as abnormal when the performance quality of the sensor is determined to fall below the given reference value.

Abstract: A failure diagnosis device for an in-cylinder pressure sensor includes an in-cylinder pressure sensor, and a controller comprised of circuitry configured to execute a diagnosis module into which a signal of the in-cylinder pressure sensor is inputted and configured to diagnose a failure of the sensor based on the signal. The diagnosis module includes a reading module configured to read the signals of the in-cylinder pressure sensor at a first timing that is a timing retarded by a specific crank angle from a compression top dead center, and at a second timing that is a timing advanced by the specific crank angle from the compression top dead center, and a failure determining module configured to determine that the in-cylinder pressure sensor has failed when the failure determining module determines that a difference between signal values at the first timing and at the second timing exceeds a predefined threshold.

Abstract: A failure diagnosis system for an in-cylinder pressure sensor is provided, which includes an in-cylinder pressure sensor, a fuel injection valve, an engine controller including an engine control module and a diagnosis module. The engine control module controls the fuel injection valve to stop the supply of fuel to the engine, when a fuel cut condition is satisfied while the automobile travels. The diagnosis module includes a limiting module configured to limit an execution of the failure diagnosis of the in-cylinder pressure sensor until the diagnosis module determines that a given period has lapsed after the stop of fuel supply to the engine. The diagnosis module reads a signal of the in-cylinder pressure sensor when the given period has lapsed after the stop of the fuel supply to the engine, and diagnoses the failure of the in-cylinder pressure sensor based on the read signal of the in-cylinder pressure sensor.

Abstract: A failure diagnosis device for an in-cylinder pressure sensor is provided, which includes an in-cylinder pressure sensor, and an engine controller comprised of circuitry configured to execute a diagnosis module into which a signal of the sensor is inputted, to diagnose a failure of the sensor based on the signal. The diagnosis module includes a reading module configured to read the signal of the sensor within a specific crank angle range, a reference phase determining module configured to determine a reference phase that is a phase of a pressure change accompanying a volume change of the combustion chamber, and a failure determining module configured to determine that the sensor has failed, when the failure determining module determines a phase of the read signal of the sensor is delayed by an amount exceeding a predefined threshold from the determined reference phase.

Abstract: A method for treating a patient who has a neutralizing antibody to a type A1 botulinum toxin. The method includes administering 150 kDa type A neurotoxin from type A2 Clostridium botulinum (A2 NTX) to the patient. In accordance with the present invention, a problem can be solved of decrease in clinical response caused by a neutralizing antibody to a type A1 botulinum toxin produced when a patient is treated with a pharmaceutical preparation containing a type A1 botulinum toxin.

Abstract: A novel type A botulinum toxin preparation is provided. A neuromuscular transmission blocking agent comprising as an active ingredient a highly purified type A botulinum toxin from Clostridium botulinum as infant botulism pathogen and a medicament for treating a disease with a muscle overactivity comprising as an active ingredient said toxin. In particular, the medicament of the present invention, as compared to the conventional known botulinum toxin preparations, has rapid efficacy of potential and is less diffusive and thus, having a broader safety margin, may be used as therapeutic medicament for decreasing local, muscle overactivity in a disease with a muscle overactivity.

Abstract: The present invention relates to a method for quantitatively measuring the muscular relaxing activity of a neurotoxin.

Abstract: The present invention relates to a method for quantitatively measuring the muscular relaxing activity of a neurotoxin.

Abstract: A method for treating a patient who has a neutralizing antibody to a type A1 botulinum toxin. The method includes administering 150 kDa type A neurotoxin from type A2 Clostridium botulinum (A2 NTX) to the patient. In accordance with the present invention, a problem can be solved of decrease in clinical response caused by a neutralizing antibody to a type A1 botulinum toxin produced when a patient is treated with a pharmaceutical preparation containing a type A1 botulinum toxin.

Abstract: A method for quantification of a titer of a neutralizing antibody to a neurotoxin is disclosed. The method comprises the steps: (a) mixing a standard sample containing a fixed amount of a neurotoxin and a test sample containing a neutralizing antibody to said neurotoxin; (b) administering the mixture obtained in step (a) into the muscle of a non-human mammal; (c) applying electric stimulus to said non-human mammal; (d) measuring a compound muscle action potential (CMAP) due to contraction of the muscle of said mammal by application of electric stimulus with an electromyograph; and (e) analyzing CMAP amplitude data obtained in step (d) for an extent of decrease in amplitude by a non-neutralized neurotoxin to thereby quantify a titer of the neutralizing antibody contained in the test sample.

Abstract: A pharmaceutical preparation for use in a patient who has a neutralizing antibody to a botulinum toxin from type A1 Clostridium botulinum (type A1 botulinum toxin), said preparation comprising as an active ingredient 150 kDa type A neurotoxin from type A2 Clostridium botulinum (A2 NTX); a medicament for treating a disease with muscle overactivity for use in a patient who has a neutralizing antibody to a type A1 botulinum toxin, said medicament comprising as an active ingredient said A2 NTX; a method for treating a patient who has a neutralizing antibody to a type A1 botulinum toxin, said method comprising administering said A2 NTX to the patient; and a method for use of A2 NTX in a patient who has said neutralizing antibody. In accordance with the present invention, a problem can be solved of decrease in clinical response caused by a neutralizing antibody to a type A1 botulinum toxin produced when a patient is treated with a pharmaceutical preparation comprising a type A1 botulinum toxin.

Abstract: A novel type A botulinum toxin preparation is provided. A neuromuscular transmission blocking agent comprising as an active ingredient a highly purified type A botulinum toxin from Clostridium botulinum as infant botulism pathogen and a medicament for treating a disease with a muscle overactivity comprising as an active ingredient said toxin. In particular, the medicament of the present invention, as compared to the conventional known botulinum toxin preparations, has rapid efficacy of potential and is less diffusive and thus, having a broader safety margin, may be used as therapeutic medicament for decreasing local, muscle overactivity in a disease with a muscle overactivity.

Abstract: The present invention relates to a method for quantitatively measuring the muscular relaxing activity of a neurotoxin.

Abstract: Disclosed herein is a rolled steel having excellent resistance to sulfide stress corrosion cracking. It comprises 0.20-0.40 wt. % C, .ltoreq.0.50 wt. % Si, .ltoreq.1.90 wt. % Mn, .ltoreq.0.06 wt. % Al, 0.0030-0.0090 wt. % N, 0.005-0.10 wt. % Nb, 0.005-0.050 wt. % Ti, and the balance iron and inevitable impurities. The rolled steel contains at least 4.times.10.sup.8 ultrafine carbonitride particles or 0.1 .mu.m or smaller per mm.sup.3 as a result that a bloom or slab having the above components is soaked, subjected at 1200.degree.-950.degree. C. to rough rolling under conditions of a total reduction percentage of 75% or lower, cooled at a cooling rate of 1.5.degree. C./sec. or higher after completion of the rough rolling and until the initiation of finish rolling, and then completed with its final rolling above the A.sub.1 transformation temperature. A process for producing the above rolled steel is also disclosed.

Abstract: The present invention relates to low alloy steel and specifically to nickel-chrome-molybdenum steel.A low alloy steel having excellent stress corrosion cracking resistance containing C:.ltoreq.0.40%, Si:.ltoreq.0.15%, Mn:.ltoreq.0.20%, P:.ltoreq.0.010%, S:.ltoreq.0.030%, Ni: 0.50 to 4.00%, Cr: 0.50 to 2.50%, Mo: 0.25 to 4.00% and V:.ltoreq.0.30%, said Si, Mn and P being fulfilled with relationship of Si+Mn+20P.ltoreq.0.30%, the remainder comprising Fe and unavoidable impurities, the prior austenite crystal grain size being in excess of 4 of ASTM crystal grain size number.

Abstract: Disclosed herein is a high strength austenitic stainless steel with excellent corrosion resistance even in oxidative enviroments, and a method for producing such stainless steel, in which the kinds and proportions of the component elements are strictly restricted, especially limiting the contents of C and N to achieve solution strengthening while preventing degradations in corrosion resistance and defects of steel ingots which would be caused if they are added excessively. Besides, V is added under coexistence with Cr and Ni to increase the strength by precipitation of carbides and nitrides of V while preventing production of Cr carbides.